We studied specific antitumor activity of a liposomal drug based on tetra-3-phenylthiophthalocyanine aluminum hydroxide (lipophthalocyan) intended for photodynamic therapy. The optimal dose and protocol for photodynamic therapy with lipophthalocyan were chosen in experiments on mice: single intravenous dose of 6 mg/kg with a 5-h interval between administration and laser exposure and irradiation energy density of 400 J/cm2. A wide spectrum antitumor activity of lipophthalocyan was demonstrated in vivo for various transplantable mouse tumors (Lewis lung epidermoid carcinoma, S37 sarcoma, and colon adenocarcinoma AKATOL). The results show the possibility of using lipophthalocyan for photodynamic therapy of tumors of surface localization (skin and mucosa tumors).
Similar content being viewed by others
References
Bol’shakov OP, Neznanov NG, Babakhanyan RV. Didactic and ethical aspects of studies on biomodels and laboratory animals. Kachestv. Klin. Prakt. 2002;(1):24-28. Russian.
Bud’ko AP, Deichman ZG, Meerovich GA, Borisova LM, Meerovich IG, Lanstova AV, Kul’bachevskaya NYu. Study of pharmacokinetics of liposomal photosensitiser based on hydroxyaluminum tetra-3-phenylthiophthalocyanine on mice. Biomedical Photonics. 2018;7(4):16-22. Russian.
Meerovich GA, Borisova LM, Bud’ko AP, Kiseleva MP, Nikolaeva LL, Meerovich IG, Lantsova AV, Chernova SV, Oborotova NA. Study of level and selectivity of liposomal form of photosensitiser hydroxyaluminum tetra-3-phenylthiophthalocyanine accumulation on transplantable mice tumor models at different ways of transplantation. Ross. Bioter. Zh. 2017;16(4):74-79. Russian.
Manual for Preclinical Studies of New Pharmacological Substances. Part I, Mironov AN, ed. Moscow, 2012. P. 642-671. Russian.
Allen CM, Sharman WM, Van Lier JE. Current status of phthalocyanines in the photodynamic therapy of cancer. J. Porphyrins Phthalocyan. 2001;5(2):161-169.
Allison RR. Future FDT. Photodiagnosis Photodyn. Ther. 2009;6(3-4):231-234.
Allison RR, Sibata CH. Oncologic photodynamic therapy photosensitizers: A clinical review. Photodiagnosis Photodyn. Ther. 2010;7(2):61-75.
Hopper C. Photodynamic therapy: a clinical reality in the treatment of cancer. Lancet Oncol. 2000;1:212-219.
Miller JD, Baron ED, Scull H, Hsia A, Berlin JC, McCormick T, Colussi V, Kenney ME, Cooper KD, Oleinick NL. Photodynamic therapy with the phthalocyanine photosensitizer Pc 4: the case experience with preclinical mechanistic and early clinical-translational studies. Toxicol. Appl. Pharmacol. 2007;224(3):290-299.
Ortel B, Shea CR, Calzavara-Pinton P. Molecular mechanisms of photodynamic therapy. Front. Biosci. (Landmark Ed). 2009;14. P.4157-4172.
Peng Q, Farrants GW, Madslien K, Bommer JC, Moan J, Danielsen HE, Nesland JM. Subcellular localization, redistribution and photobleaching of sulfonatedaluminumphthalocyanines in a human melanoma cell line. Int. J. Cancer. 1991;49(2):290-295.
Sanarova EV, Lantsova AV, Polozkova AP, Orlova OL, Meerovich IG, Borisova LM, Kiseleva MP, Smirnova ZS, Kul’bachevskaya NY, Konyaeva OI, Oborotova NA. Effectiveness of liposomal system of delivery of hydrophobic antineoplastic Thiosens photosensitizer. Nanotechnologies in Russia. 2015;10(5-6):492-500.
Sanarova E, Meerovich I, Lantsova A, Kotova E, Shprakh Z, Polozkova A, Orlova O, Borisova L, Smirnova Z, Oborotova N, Baryshnikov A, Meerovich G, Lukyanets E. Thiosens liposomal dosage form technology development and photodynamic efficiency assessment. J. Drug Deliv. Sci. Technol. 2014;24(4):315-319.
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 168, No. 9, pp. 332-337, September, 2019
Rights and permissions
About this article
Cite this article
Lantsova, A.V., Borisova, L.M., Meerovich, G.A. et al. Analysis of Antitumor Activity of the Liposomal Photosensitizer Lipophthalocyan. Bull Exp Biol Med 168, 361–365 (2020). https://doi.org/10.1007/s10517-020-04709-9
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-020-04709-9